The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Removes Boxed Warning for Combination Asthma Treatment

FDA Removes Boxed Warning for Combination Asthma Treatment

January 10, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 2011, the U.S. Food and Drug Administration (FDA) mandated pharmaceutical manufacturers of long-acting beta agonists (LABAs) to conduct post-market clinical trials evaluating the safety of LABAs in combined treatment with inhaled corticosteroids (ICSs).1 In mid-December 2017, the results of those safety trials were published.

You Might Also Like
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • FDA Strengthens Warning Label for Certain Antiinflammatory Drugs
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
Also By This Author
  • Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

The FDA reviewed four large clinical safety trials (N=41,297), which showed that asthma treatment with LABAs combined with ICSs does not result in significantly more serious asthma-related hospitalizations, intubations or deaths than treatment with ICS alone.2 Three of the trials involved patients 12 years and older, and one trial involved children aged 4 to 11 years. All patients were treated for six months to evaluate serious asthma outcomes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After reviewing these study results, the FDA has removed the boxed warning about asthma-related deaths from the drug labels of medications containing both LABA and ICS. Now, descriptions of these four clinical trials are included in the Warnings and Precautions section of the drug labels. But the labels of these combination medications will retain a Warning and Precaution related to the increased risk of asthma-related death when LABAs are used without an ICS to treat asthma. These products include: Advair and Airduo RespiClick (fluticasone and salmeterol), Breo Ellipta (fluticasone & vilanterol), Dulera (mometasone and formoterol) and Symbicort (budesonide and formoterol).

Additionally, because LABAs are associated with an increased risk of asthma-related death when used as a monotherapy to treat asthma (without an ICS), the boxed warning stating such will remain on the labels of all single-ingredient LABA products.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. FDA drug safety communication: FDA requires post-market safety trials for long-acting beta-agonists (LABAs). 2011 Apr 15.
  2. U.S. Food and Drug Administration. FDA drug safety communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). 2017 Dec 20.

Filed Under: Drug Updates Tagged With: asthma, Drug Safety, inhaled corticosteroids, long-acting beta agonists, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • FDA Strengthens Warning Label for Certain Antiinflammatory Drugs
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)